Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: A randomised phase 2 study

The Lancet Oncology

Volumn 15, Issue 11, 2014, Pages 1207-1214

  Liu, Joyce F ^a   Barry, William T ^a   Birrer, Michael ^b   Lee, Jung Min ^c   Buckanovich, Ronald J ^d   Fleming, Gini F ^e   Rimel, B J ^f   Buss, Mary K ^g   Nattam, Sreenivasa ^h   Hurteau, Jean ⁱ   Luo, Weixiu ^a   Quy, Philippa ^a   Whalen, Christin ^a   Obermayer, Lisa ^a   Lee, Hang ^b   Winer, Eric P ^a   Kohn, Elise C ^c   Ivy, S Percy ^c   Matulonis, Ursula A ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d UNIVERSITY OF MICHIGAN   (United States)

^e SECTION OF HEMATOLOGY ONCOLOGY   (United States)

^f CEDARS SINAI MEDICAL CENTER   (United States)

^g BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^h Fort Wayne Medical Oncology and Hematology   (United States)

ⁱ NORTH SHORE UNIVERSITY HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; CEDIRANIB; OLAPARIB; PLATINUM COMPLEX; ANTINEOPLASTIC AGENT; CISPLATIN; PHTHALAZINE DERIVATIVE; PIPERAZINE DERIVATIVE; QUINAZOLINE DERIVATIVE;

ADULT; ANEMIA; ANTIANGIOGENIC THERAPY; ARTICLE; AVASCULAR NECROSIS; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER RECURRENCE; CANCER SURVIVAL; CAUSE OF DEATH; CLINICAL ARTICLE; CONTROLLED STUDY; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG RESPONSE; DRUG SENSITIVITY; ENDOMETRIOID CARCINOMA; FATIGUE; FEMALE; GENE MUTATION; HEADACHE; HUMAN; HYPERTENSION; HYPOTHYROIDISM; LEUKOCYTE COUNT; MONOTHERAPY; MYELODYSPLASTIC SYNDROME; NAUSEA; NEUTROPHIL COUNT; OVARY CANCER; OVERALL SURVIVAL; PERITONEUM CANCER; PHASE 2 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RECOMMENDED DRUG DOSE; RECTOVAGINAL FISTULA; SIDE EFFECT; THROMBOCYTE COUNT; UTERINE TUBE CARCINOMA; WEIGHT REDUCTION; AGED; CLINICAL TRIAL; COMPARATIVE STUDY; CONFIDENCE INTERVAL; DISEASE FREE SURVIVAL; DOSE RESPONSE; DRUG ADMINISTRATION; FOLLOW UP; KAPLAN MEIER METHOD; MAXIMUM TOLERATED DOSE; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PATHOLOGY; RISK ASSESSMENT; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TUMOR RECURRENCE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; CONFIDENCE INTERVALS; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; KAPLAN-MEIER ESTIMATE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PHTHALAZINES; PIPERAZINES; QUINAZOLINES; RISK ASSESSMENT; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84908134454     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(14)70391-2     Document Type: Article

References (31)

1. Siegel R, Ma J, Zou Z, Jemal A Cancer statistics, 2014. CA Cancer J Clin 2014, 64:9-29.
2. Jayson GC, Kohn EC, Kitchener HC, Ledermann JA Ovarian cancer. Lancet 2014, published online April 17. http://dx.doi.org/10.1016/S0140-6736(13)62146-7.
3. Bryant HE, Schultz N, Thomas HD, et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 2005, 434:913-917.
4. Farmer H, McCabe N, Lord CJ, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005, 434:917-921.
5. Integrated genomic analyses of ovarian carcinoma. Nature 2011, 474:609-615. Cancer Genome Atlas Research Network.
6. Walsh T, Casadei S, Lee MK, et al. Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing. Proc Natl Acad Sci USA 2011, 108:18032-18037.
7. Fong PC, Boss DS, Yap TA, et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 2009, 361:123-134.
8. Fong PC, Yap TA, Boss DS, et al. Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. J Clin Oncol 2010, 28:2512-2519.
9. Audeh MW, Carmichael J, Penson RT, et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet 2010, 376:245-251.
10. Gelmon KA, Tischkowitz M, Mackay H, et al. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study. Lancet Oncol 2011, 12:852-861.
11. Tutt A, Robson M, Garber JE, et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet 2010, 376:235-244.
12. Ledermann J, Harter P, Gourley C, et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med 2012, 366:1382-1392.
13. Ledermann J, Harter P, Gourley C, et al. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancet Oncol 2014, 15:852-861.
14. Burger RA, Sill MW, Monk BJ, Greer BE, Sorosky JI Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study. J Clin Oncol 2007, 25:5165-5171.
15. Cannistra SA, Matulonis UA, Penson RT, et al. Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol 2007, 25:5180-5186.
16. Matulonis UA, Berlin S, Ivy P, et al. Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer. J Clin Oncol 2009, 27:5601-5606.
17. Ledermann J, Perren TJ, Raja FA, et al., Randomised double-blind phase III trial of cediranib (AZD 2171) in relapsed platinum sensitive ovarian cancer: results of the ICON6 trial. Presented at the 2013 European Cancer Congress, Amsterdam, Netherlands, Sept 13, 2013; abstr 10.
18. Tentori L, Lacal PM, Muzi A, et al. Poly(ADP-ribose) polymerase (PARP) inhibition or PARP-1 gene deletion reduces angiogenesis. Eur J Cancer 2007, 43:2124-2133.
19. Bindra RS, Gibson SL, Meng A, et al. Hypoxia-induced down-regulation of BRCA1 expression by E2Fs. Cancer Res 2005, 65:11597-11604.
20. Bindra RS, Schaffer PJ, Meng A, et al. Down-regulation of Rad51 and decreased homologous recombination in hypoxic cancer cells. Mol Cell Biol 2004, 24:8504-8518.
21. Lim JJ, Yang K, Taylor-Harding B, Wiedemeyer WR, Buckanovich RJ VEGFR3 inhibition chemosensitizes ovarian cancer stemlike cells through down-regulation of BRCA1 and BRCA2. Neoplasia 2014, 16:343-353.
22. Liu JF, Tolaney SM, Birrer M, et al. A phase 1 trial of the poly(ADP-ribose) polymerase inhibitor olaparib (AZD2281) in combination with the anti-angiogenic cediranib (AZD2171) in recurrent epithelial ovarian or triple-negative breast cancer. Eur J Cancer 2013, 49:2972-2978.
23. Dean E, Middleton MR, Pwint T, et al. Phase I study to assess the safety and tolerability of olaparib in combination with bevacizumab in patients with advanced solid tumours. Br J Cancer 2012, 106:468-474.
24. Kaye SB, Lubinski J, Matulonis U, et al. Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer. J Clin Oncol 2012, 30:372-379.
25. Hirte H, Vidal L, Fleming GF, et al. A phase II study of cediranib (AZD2171) in recurrent or persistent ovarian, peritoneal or fallopian tube cancer: final results of a PMH, Chicago, and California consortia trial. J Clin Oncol 2008, 26. abstr 5521.
26. Aghajanian C, Blank SV, Goff BA, et al. OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol 2012, 30:2039-2045.
27. Parmar MK, Ledermann JA, Colombo N, et al. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet 2003, 361:2099-2106.
28. Pfisterer J, Plante M, Vergote I, et al. Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. J Clin Oncol 2006, 24:4699-4707.
29. Pujade-Lauraine E, Wagner U, Aavall-Lundqvist E, et al. Pegylated liposomal doxorubicin and carboplatin compared with paclitaxel and carboplatin for patients with platinum-sensitive ovarian cancer in late relapse. J Clin Oncol 2010, 28:3323-3329.
30. NCCN guidelines: ovarian cancer National Comprehensive Cancer Network, (accessed June 10, 2014). http://www.nccn.org.
31. Moon DH, Lee JM, Noonan AM, et al. Deleterious BRCA1/2 mutation is an independent risk factor for carboplatin hypersensitivity reactions. Br J Cancer 2013, 109:1072-1078.